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The focus of this paper is to summarize the current knowledge on visual pathway damage in neuromyelitis optica (NMO) assessed
by magnetic resonance imaging (MRI) and optical coherence tomography (OCT).
1. Introduction
Neuromyelitis optica (NMO, Devic’s syndrome) is a rare
inflammatory autoimmune central nervous system (CNS)
disorder clinically characterised by mostly severe attacks to
the optic nerves and the spinal cord [1]. For a long time,
NMO was regarded as variant of multiple sclerosis (MS);
however, recent increasing evidence points to a distinct
pathogenesis. A milestone was the detection of a highly
specific biomarker for NMO, the so-called NMO-IgG, the
target antigen of which was shown to be the most abundant
CNS water channel aquaporin-4 (AQP4) [2, 3]. Various
assays for the detection of antibodies to AQP4 have since
been developed which has facilitated the clinically relevant
distinction of NMO fromMS [4, 5]. Antibodies to AQP4 are
detectable in 60 to 90% of NMO patients with a specificity
of 91–100%. In contrast to previous beliefs, NMO is today
regarded as a relapsing disease in 80–90% of patients. With
the detection of AQP4 antibodies, the clinical spectrum
of NMO has broadened, and currently also AQP4-positive
longitudinally extensive transverse myelitis (LETM) and
AQP4-positive recurrent optic neuritis are regarded as part
of NMO spectrum disorders (NMOSDs) [1, 6].
Studies in MS have shown that neuroinflammation and
neurodegeneration can lead to an affection of different parts
of the visual pathway, including intraretinal inflammation,
retinal neurodegeneration, retinal nerve axonal degeneration
as well as pathological changes in the optic tract, the lateral
geniculate nucleus, the optic radiation, and the visual cortex
[7–11].
The aim of this paper is to give an overview on the recent
research results on a similar or different involvement of the
visual pathway in NMO pathology as assessed by magnetic
resonance imaging (MRI) and optical coherence tomography
(OCT).
2. Visual Dysfunction in NMO
In comparison to optic neuritis (ON) in MS, attacks to the
optic nerve in NMO occur more often bilaterally and show
a poor and incomplete remission of visual functions despite
anti-inflammatory and immunosuppressive treatment. At a
mean disease duration of 7.7 years after disease onset, more
than half of patients with relapsing NMO are functionally
blind in at least one eye [12].
3. Imaging
3.1. Magnetic Resonance Imaging
3.1.1. Spinal Cord. In case of myelitis, spinal cord MRI may
reveal a characteristic feature: centrally located longitudinal
lesions expanding over 3 or more vertebral segments which
may be associated with cord swelling and enhancement
with intravenous gadolinium administration. These findings
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have—in combination with a nondiagnostic brain MRI at
disease onset—a specificity of 90% for NMO [13].
3.1.2. Brain. From a clinical standpoint, abnormal brain
MRI was until recently considered to argue against an NMO
diagnosis. However, several publications in the past few years
have highlighted that in NMO various brain lesions may
be present at onset or during the course of the disease. A
high percentage of NMO patients develop nonspecific brain
lesions after diagnosis (60% in the series by Pittock et al. [14],
85% in a Chinese series by Li et al. [15], and in 10% of 60
patients brain lesions met the diagnostic criteria for MS [14].
Another 10% have brain lesions in periependymal regions
(e.g., hypothalamus, periaqueductal brainstem) which are
rich in AQP4 [15–19]. In contrast to MS, extensive and
diffuse widespread white matter abnormalities have been
described by various groups. Recently, also large edematous
callosal lesions were reported in 4 of 22 NMO patients [20].
Additional MR techniques which are not routinely
implemented in clinical practice are magnetization transfer
imaging (MTI), diffusion tensor imaging (DTI), and MR
spectroscopy (MRS). MTI is a technique that analyses the
energy transfer from matrix bound water to free water
hydrogen nuclei and thereby allows to evaluate the integrity
of an anatomical structure. DTI measures the direction-
dependent diffusibility restriction of water, and the resulting
data can be computed to characterise fibrous structures, like
the optic radiation. MRS is different from other imaging
techniques, as it does not provide structural information,
but information about ongoing metabolic processes by a
concentrationmeasurement ofmetabolites representative for
energy metabolism, integrity of cell membranes, axonal or
neuronal integrity and others. These methods have revealed
damage to the normal-appearing gray matter but no [21–
24] or only minimal abnormalities in the normal-appearing
white matter [25]. In contrast, a recent DTI study by Yu
and colleagues [26] reported an increased diffusivity of
the corticospinal tract and the optic radiations but not of
the corpus callosum and the cingulum in NMO patients
compared to controls, and the authors concluded that
the abnormal diffusion was restricted to the regions with
connections to the optic nerves and the spinal cord, thus
arguing for axonal degeneration secondary to lesions in the
optic nerve and the spinal cord.
3.1.3. Visual Pathway: Optic Nerve and Optic Radiation.
MR Imaging studies aimed to visualize optic nerve damage
in NMO are sparse. Li et al. reported optic nerve sheath
thickening in 16 of 33 patients, all of whom had symptoms
of recurrent ON [15].Wang and colleagues found optic nerve
hyperintensities in 6 of 10 patients with available optic nerve
MRI [19]. Enhancement of the optic nerves with intravenous
gadolinium administration was detected in 4 patients in
whom MRI was performed within 6 weeks of onset of acute
ON. Similar observations have been made in a comparable
study [27]. However, as similar findings have been described
in MS optic neuritis [28], it is doubtful whether the
aforementioned findings are specific features of NMO or
rather indicate optic nerve inflammation irrespective of the
underlying condition. Lin et al. reported the possibility to
discriminate NMO from MS based on DTI data. However,
no tract-specific analysis was performed here [29]. The only
MRI study to date that assessed the retrogeniculate part of
the visual pathway in NMO by DTI reported an increased
diffusivity of the optic radiation [26]. To our knowledge,
there is no bigger study onMT imaging of the visual pathway
in NMO patients.
3.2. Optical Coherence Tomography. OCT is a noninvasive
and reproducible technique to study unmyelinated retinal
axons with a high spatial resolution in vivo and to quantify
the thickness of the peripapillary retinal nerve fiber layer
(RNFL), fovea, and macula [30]. In MS patients, OCT
has been consistently shown to detect thinning of the
RNFL which is most probably due to a diffuse damage of
retinal axons that occurs at least in part independent of
a previous or present attack of ON [31–33]. Against this
background, OCT might prove as a valuable tool for the
detection and monitoring of axonal damage in MS and
other inflammatory CNS conditions such as NMO. Several
groups have investigated anterior visual pathway damage in
NMO by OCT in comparison to healthy controls or MS
patients. The first published study on OCT in NMO by
de Seze and colleagues [34] reported dramatically reduced
average RNFL thickness in NMO patients as compared
to healthy controls (77.9 µm versus 102.3 µm) and a good
correlation between OCT results and both visual acuity
and visual evoked potential latencies. Interestingly, among
patients at high risk for NMO (recurrent ON of LETM), only
those with recurrent ON had a similarly severe reduction
of average RNFL thickness (74.2 µm) in contrast to those
with recurrent myelitis who did not differ from controls
with respect to average RNFL thickness (101.8 µm versus
102.3 µm). Another recent OCT study by Naismith and
colleagues compared RNFL measurements in NMO patients
to MS [35]. In accordance with the clinical experience of a
more severe loss of visual function in NMO compared to
MS following ON, RNFL thickness was significantly thinner
in NMO patients than in MS ones after ON suggesting
a more profound axon loss in the optic nerve in NMO.
Similar results were obtained by Ratchford et al. [36] who
estimated a first episode of ON to cause 24 µm more loss
of RNFL thickness in NMO than in relapsing-remitting MS.
Moreover, also macular volume was significantly reduced
in NMO ON eyes both versus MS and healthy controls.
Interestingly, eyes in the subgroup of patients with LETM
and unaffected NMO eyes were not different from controls.
The difference in RNFL thickness between ON and non-
ON eyes was much greater in NMO patients than in MS
ones (34.3 µm versus 9.6 µm). This may suggest that retinal
axonal damage in NMO is predominantly linked to attacks of
ON while in MS thinning of the RNFL has been reported—
albeit to a lesser extent—also in non-ON eyes [32, 33].
Other hypothetical explanations may be a more frequent
occurrence of subclinical optic neuritis in MS than in NMO,
or MS lesions in the chiasm or optic tracts causing bilateral
RNFL involvement [35].
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It is worth to critically discuss the significance of OCT
for monitoring axonal damage. On one hand the validity of
OCTmeasurements in the past was limited by device-specific
measurement variations of the time-domain tomographs in
the range of a suspected effect, for example, for RNFLT
changes over time. It is expected that the novel spectral-
domain OCT devices provide an improved spatial resolution
and a better retest-reliability in the future and thereby help
to give a more precise description of damage to the visual
pathway and its underlying pathogenetic correlate [37, 38].
On the other hand, there is increasing evidence that OCT
measurements do not reflect axonal damage exclusively, but
could also be affected by intraretinal inflammation or retinal
neuronal degeneration, as described in a recent neuropatho-
logical study on postmortem analysis on postmortem MS
brain tissue by Green et al. [7].
3.3. Is There an Interplay of Damage to the Anterior and the
Posterior Visual Pathway? Imaging the entire visual pathway
in inflammatory CNS conditions with clinical optic nerve
involvement may provide the opportunity to study the
relationship between damage to the anterior (optic nerves,
chiasm, optic tracts) and attrition to the posterior visual
pathway (lateral geniculate nucleus (LGN), optic radiations,
visual cortex in the occipital lobe). It is conceivable that
damage to one part of the visual pathway may cause—
via antero- or retrograde transsynaptic degeneration—an
alteration in the other part of the visual pathway. In the
past decades, transsynaptic degeneration in the visual system
has been shown in various animal models [39–43]. A recent
OCT study showed significant RNFL thinning in patients
with retrogeniculate lesions (congenital or acquired occipital
lobe damage) [44]. In MS, a histopathological study revealed
neuronal loss in the LGN [9]. Several other groups have
since addressed the question of transsynaptic degeneration
by different imaging techniques in MS patients in vivo.
Sepulcre and colleagues demonstrated that atrophy of the
LGN was related to the presence of lesions specifically in
the optic radiations but not in the rest of the brain [10].
Ciccarelli et al. examined patients one year after an episode of
ON and found reduced connectivity in the optic radiations,
suggesting both transsynaptic effects and axonal loss in the
optic radiations related to LGN neuronal loss [45]. Audoin et
al. reported a decreased visual cortex magnetization transfer
ratio in patients with optic neuritis [11]. Dasenbrock et al.,
in a combined DTI-OCT study in patients with MS and
healthy controls, reported a significant association of optic
tract diffusion abnormalities with RNFL thinning [46]. In a
large cross-sectional study comprising 86 relapsing-remitting
MS patients, we investigated the association of RNFL changes
with brain atrophy (“brain parenchymal fraction”, BPF)
and n-acetyl-aspartate (NAA) concentrations as a marker of
neuroaxonal integrity in the visual cortex and the normal-
appearing white matter (NAWM) (Pfueller et al., in revision).
We found a significant correlation of RNFL thickness with
visual cortex NAA, and patients with a previous history
of ON on one or both eyes had significantly lower visual
cortex NAA values than patients without history of optic
neuritis. In contrast, NAWM NAA did not correlate with
RNFL thickness, and there was no difference in NAWMNAA
between patients with and without ON. BPF also correlated
with RNFL thickness, and in a multivariate analysis, both
BPF and visual cortex NAA were independently associated
with RNFL thickness. Our data suggest that attacks to the
optic nerve in MS have a detrimental impact on parts of
the visual pathway as remote as the visual cortex, further
supporting the assumption of transsynaptic degeneration in
the visual pathway.
In NMO, no studies have to date assessed the entire
visual pathway by a combination of various imaging tech-
niques (e.g., OCT and optic nerve MRI for the anterior
visual pathway, DTI or MRS for the retrogeniculate visual
pathway). It is, however, conceivable, that damage to one
part of the visual pathway has an impact on the other
part also in NMO, as transsynaptic degeneration has been
shown in different neurological conditions as delineated
above and also in ophthalmologic diseases such as glaucoma
[47], (reviewed in [48]). The study by Yu and colleagues
showing increased diffusivity in the optic radiations of
NMO patients supports this notion [26]. Studying the entire
visual pathway by a combination of OCT and different MRI
techniques may provide additional insights into the interplay
between damage to the anterior and the retrogeniculate
part of the visual pathway, as these measurements are far
less likely to be confounded by focal inflammatory and
demyelinating lesions in the brain as is the case in MS. The
absence of these lesions should also facilitate the volumetric
analysis of different parts of the visual pathway to address
the hypothesis of transsynaptical degeneration and also to
assess the dynamics of degenerative processes triggered by
single inflammatory events, such as acute optic neuritis.
To our knowledge, this approach has not been addressed
systematically in a larger cohort of NMO patients.
To summarize, the repertoire of available imaging tech-
niques (including DTI, MTI, and MR spectroscopy) has not
been used yet to its full potential; especially studies focusing
on the visual pathway and its anatomical correlates are
still missing. Addressing these points could help to identify
significant differences between NMO and MS and give fur-
ther insight into NMO-specific damage processes as well as
into transsynaptical damage processes independent of their
underlying condition. Of special interest will be the question,
whether neurodegeneration in NMO can only occur in the
context of acute or previous neuroinflammation or whether
there is evidence for diffuse, chronic axonal, and neuronal
degeneration independent of acute neuroinflammation, as
was shown for MS.
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